| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 702.8 | 720.3 | 590.5 |
| Other income | 0.8 | 0.8 | 0.3 |
| Total income | 703.6 | 721.1 | 590.8 |
| Profit before exceptional items & tax | 71.3 | 70.4 | 51.1 |
| Exceptional items | 2.1 | 0.0 | 0.0 |
| Profit before tax | 69.2 | 70.4 | 51.1 |
| Net profit | 50.1 | 55.3 | 54.0 |
| Operating margin | 9.8% | 9.8% | 8.6% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -7.20% |
|---|---|
| Net profit, quarter on quarter | -9.40% |
| Revenue, year on year | +19.00% |
| Operating profit, year on year | -8.20% |
| Operating profit, quarter on quarter | -9.50% |
NSE results filing, NSE: AARTIDRUGS. Figures extracted from the filing.
Aarti Drugs Ltd: key numbers
- Share price
- ₹427.40
- Market cap
- ₹3,901 Cr
- Revenue (annual)
- ₹2,565 Cr
- Net profit (annual)
- ₹194.9 Cr
- P/E (TTM)
- 20.4×Sector 50.4×
- Promoter holding
- 54.43%-0.60% QoQ
- FII holding
- 1.52%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aarti Drugs Ltd
All →Aarti Drugs Management Change
Aarti Drugs Ltd announced the retirement of Director Uday M. Patil and the appointment of new directors, including Adhish P. Patil as the Managing Director.
Aarti Drugs Investor Presentation: Key Takeaways
Aarti Drugs reports Q1 FY27 revenue of ₹704 Cr, up 19% YoY. Management focuses on scaling regulated market sales through high-margin formulations and oncology backward integration.
Aarti Drugs Annual General Meeting
Aarti Drugs Limited conducted its 41st Annual General Meeting on September 26, 2026, to consider various ordinary and special business resolutions.
Aarti Drugs Annual General Meeting
Aarti Drugs Ltd has issued a notice for its 41st Annual General Meeting scheduled for September 26, 2026. The agenda includes financial statements and director appointments.
Aarti Drugs Annual Report
Aarti Drugs has released its Annual Report for FY 2025-26 and notice for its 41st Annual General Meeting scheduled for September 26, 2026.
Aarti Drugs Investor Presentation: Key Takeaways
Aarti Drugs reported Q1 FY27 revenue of ₹703.6 Cr, up 19% YoY, with EBITDA rising 30% to ₹96.9 Cr. Strategy focuses on backward integration at Sayakha and USFDA-regulated market expansion.